The question of whether BPC-157 might ever be legally available through U.S. compounding pharmacies comes down to one thing: the 503A bulks list. Understanding how this list works — and what it takes to get onto it — is essential background for the July 2026 FDA advisory discussion.
What is the 503A bulks list?
Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies. These are state-licensed pharmacies that prepare custom medications for individual patients based on a valid prescription.
Under 503A, a compounder can use a drug substance that is:
- A component of an FDA-approved drug, or
- Recognized in the United States Pharmacopeia (USP) or National Formulary (NF), or
- On the FDA's 503A bulks list
BPC-157 does not meet the first two criteria. This means the only path to compliant 503A compounding is placement on the bulks list — which is exactly what the July 2026 PCAC discussion is about.
How does a substance get onto the 503A bulks list?
The process involves several steps:
- Nomination. Anyone — a physician, patient, compounder, or trade association — can nominate a substance for evaluation. Nominations must include supporting information about the substance's chemistry, safety, and clinical use.
- FDA review. The FDA evaluates the nomination against defined criteria: whether there is a clinical need for the compounded drug, whether the substance meets quality standards, and whether there are safety concerns.
- PCAC review. For many substances, the FDA sends the substance to the PCAC for public discussion and an advisory vote. This is a formal public meeting with expert deliberation.
- Proposed rule. If the FDA proceeds favorably, it publishes a notice of proposed rulemaking to add the substance to the 503A bulks list. This opens a public comment period.
- Final rule. After considering public comments, the FDA may issue a final rule adding the substance to the list. Only at this point is the substance legally available for 503A compounding.
What criteria does the FDA use?
The FDA evaluates bulk drug substance nominations against several criteria established in the statute and FDA guidance:
- Clinical need: Is there a documented patient need for a compounded version that cannot be met by an approved drug?
- Safety: Are there known safety concerns about the substance? Are there adequate data to characterize risks?
- Quality: Can the substance be consistently manufactured to meet purity and potency standards?
- Evidence: What does the scientific literature say about the substance's pharmacological effects?
Where does BPC-157 stand in this process?
BPC-157-related substances were nominated for the 503A bulks list and advanced to the PCAC discussion stage. The July 23, 2026 meeting is where the PCAC will formally review the available evidence and make its recommendation to the FDA.
A favorable PCAC recommendation would move the process to the proposed rule stage. A negative recommendation would likely end the process — at least until new evidence emerges. A mixed recommendation could mean additional study requirements before the process continues.
How long does the full process take?
From favorable PCAC recommendation to final rule, the rulemaking process typically takes many additional months to over a year. This is because the proposed rule stage involves public notice, a comment period (often 60–90 days), comment review, and drafting of a final rule. Regulatory timelines vary significantly based on agency resources and the complexity of the substance.
The bottom line: even the most favorable possible outcome on July 23, 2026 would not translate to immediate access through licensed compounding pharmacies.
